Inflammatory profiles relate to survival in subtypes of amyotrophic lateral sclerosis
Open Access
- 1 May 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
Abstract
Objective To investigate inflammatory cytokines in patients with motor neuron disease (MND) evaluating the putative contribution of amyotrophic lateral sclerosis (ALS)-causing gene variants. Methods This study is a retrospective case series with prospective follow-up (1994–2016) of 248 patients with MND, of whom 164 had ALS who were screened for mutations in the genes for SOD1 and C9orf72. Paired CSF and plasma were collected at the diagnostic evaluation before treatment. A panel of cytokines were measured blindly via digital ELISA on the Simoa platform. Results Time from disease onset to death was longer for patients with ALS-causing SOD1 mutations (mSOD1, n = 24) than those with C9orf72 hexanucleotide repeat expansion (C9orf72HRE) ALS (n = 19; q = 0.001) and other ALS (OALS) (n = 119; q = 0.0008). Patients with OALS had higher CSF tumor necrosis factor alpha (TNF-α) compared with those with C9orf72HRE ALS (q = 0.014). Patients with C9orf72HRE ALS had higher CSF interferon alpha compared with those with OALS and mSOD1 ALS (q = 0.042 and q = 0.042). In patients with ALS, the survival was negatively correlated with plasma interleukin (IL) 10 (hazard ratio [HR] 1.17, 95% CI 1.05–1.30). Plasma TNF-α, IL-10, and TNF-related apoptosis-inducing ligand (TRAIL) (HR 1.01 [1.00–1.02], 1.15 [1.02–1.30], and 1.01 [1.00–1.01], respectively) of patients with OALS, plasma IL-1β (HR 5.90 [1.27–27.5]) of patients with C9orf72HRE ALS, and CSF TRAIL (10.5 [1.12–98.6]) of patients with mSOD1 ALS all correlated negatively with survival. Conclusions Differences in survival times in ALS subtypes were correlated with cytokine levels, suggesting specific immune responses related to ALS genetic variants.This publication has 46 references indexed in Scilit:
- Protein aggregation in amyotrophic lateral sclerosisActa Neuropathologica, 2013
- Microglial Activation Correlates with Disease Progression and Upper Motor Neuron Clinical Symptoms in Amyotrophic Lateral SclerosisPLOS ONE, 2012
- EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) – revised report of an EFNS task forceEuropean Journal of Neurology, 2011
- Physiology of MicrogliaPhysiological Reviews, 2011
- Activation of interferon signaling pathways in spinal cord astrocytes from an ALS mouse modelGlia, 2011
- Innate and adaptive immunity in amyotrophic lateral sclerosis: Evidence of complement activationNeurobiology of Disease, 2011
- Prognostic factors in ALS: A critical reviewAmyotrophic Lateral Sclerosis, 2009
- Onset and Progression in Inherited ALS Determined by Motor Neurons and MicrogliaScience, 2006
- Interleukin-10andRelatedCytokines andReceptorsAnnual Review of Immunology, 2004
- Functional Role of Caspase-1 and Caspase-3 in an ALS Transgenic Mouse ModelScience, 2000